Provided by Tiger Fintech (Singapore) Pte. Ltd.

Corvus Pharmaceuticals

3.95
-0.0300-0.75%
Post-market: 3.93-0.0200-0.51%16:51 EDT
Volume:313.95K
Turnover:1.25M
Market Cap:304.60M
PE:-3.97
High:4.07
Open:4.02
Low:3.94
Close:3.98
Loading ...

Director and 10% Owner Peter A. Thompson Reports Disposal of Common Shares of Corvus Pharmaceuticals Inc

Reuters
·
02 Jul

Corvus Pharmaceuticals Gets China Nod to Begin Atopic Dermatitis Drug Trial

MT Newswires Live
·
25 Jun

BRIEF-Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Received IND Approval For A Phase 1B/2 Clinical Trial Of Soquelitinib

Reuters
·
25 Jun

Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Received Ind Approval for a Phase 1B/2 Clinical Trial of Soquelitinib in China for the Treatment of Atopic Dermatitis

THOMSON REUTERS
·
25 Jun

Mizuho Securities Remains a Buy on Corvus Pharmaceuticals (CRVS)

TIPRANKS
·
25 Jun

Corvus Pharmaceuticals Inc. Conducted Annual Stockholders Meeting

Reuters
·
14 Jun

Cantor Fitzgerald Remains a Buy on Corvus Pharmaceuticals (CRVS)

TIPRANKS
·
12 Jun

Corvus Pharmaceuticals Unveils Promising Interim Results from Phase 1 Trial of Soquelitinib for Atopic Dermatitis

Reuters
·
04 Jun

Corvus Pharmaceuticals Inc - All Cohorts Show Statistically Significant Difference From Placebo at Day 28

THOMSON REUTERS
·
04 Jun

Corvus Pharmaceuticals Announces Full Data From Cohort 3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

THOMSON REUTERS
·
04 Jun

Corvus Pharmaceuticals Inc - Cohort 3 Shows Earlier and Deeper Responses Compared to Cohorts 1-2

THOMSON REUTERS
·
04 Jun

Corvus Pharmaceuticals Inc - Cohort 3 Shows Clinically Meaningful Reduction in Itch by Day 8

THOMSON REUTERS
·
04 Jun

Mizuho Adjusts Price Target on Corvus Pharmaceuticals to $11 From $12, Maintains Outperform Rating

MT Newswires Live
·
20 May

Corvus Pharmaceuticals Reports Strong Q1 2025 Earnings

TIPRANKS
·
10 May

Corvus Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
10 May

Corvus Pharmaceuticals Price Target Raised to $17.00/Share From $15.00 by Oppenheimer

Dow Jones
·
10 May

Corvus Pharmaceuticals Up Over 26%, on Pace for Largest Percent Increase Since May 2023 -- Data Talk

Dow Jones
·
09 May

Wall Street Set to Open Higher Friday as Investors Calmed by Trade Talks

MT Newswires Live
·
09 May

Oppenheimer Adjusts Corvus Pharmaceuticals Price Target to $17 From $15, Maintains Outperform Rating

MT Newswires Live
·
09 May

Corvus Pharmaceuticals Shares Surge on Study Data Evaluating Soquelitinib

Dow Jones
·
09 May